Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Atezolizumab & Non-Small-Cell-Lung-Cancer (NSCLC)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Regulatory status:

In the context of Atezolizumab & Non-Small-Cell-Lung-Cancer (NSCLC), Atezolizumab is FDA and EMA approved for the treatment of non-small-cell lung cancer (NSCLC) in multiple settings, including as first-line and second-line therapy for metastatic disease, and as adjuvant therapy after resection and chemotherapy. Atezolizumab approval was independent of PD-L1 status (1).

Clinical data:

The clinical phase III/IV treatment trial, identified as NCT03285763 (TAIL), demons…

References (Sources)

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Herbst et al. 2020a N Engl J Med 383: 1328-1339
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Gong et al. 2018
Review
Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel
Gandara et al. 2021
Immune checkpoint inhibitors and non-small-cell lung cancer management: 2018 update
Abdel-Rahman & Morris 2019
Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer
Ardizzoni et al. 2021
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
Cho et al. 2022 The Lancet Oncology 23(6): 781-792

AI Chat

7/1/2026

Chat with our artificial intelligence: